## Stuart L Schreiber

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8101657/publications.pdf

Version: 2024-02-01

281 papers 58,767 citations

97 h-index 232 g-index

341 all docs

341 docs citations

times ranked

341

63851 citing authors

#	Article	IF	CITATIONS
1	Crystallization-Based Synthetic Route to Antimalarial Agent BRD5018: Diazocene Ring Formation via a Staudinger-aza-Wittig Reaction on an Azetidine-Ribose Template. Organic Process Research and Development, 2022, 26, 817-831.	1.3	5
2	PALP: A rapid imaging technique for stratifying ferroptosis sensitivity in normal and tumor tissues in situ. Cell Chemical Biology, 2022, 29, 157-170.e6.	2.5	17
3	Bicyclic azetidines target acute and chronic stages of Toxoplasma gondii by inhibiting parasite phenylalanyl t-RNA synthetase. Nature Communications, 2022, 13, 459.	5.8	7
4	Persister cancer cells: Iron addiction and vulnerability to ferroptosis. Molecular Cell, 2022, 82, 728-740.	4.5	92
5	Modular Synthesis of Cyclopropaneâ€Fused <i>N</i> à€Heterocycles Enabled by Underexplored Diazo Reagents. Angewandte Chemie - International Edition, 2022, 61, .	7.2	10
6	Inhibition of Plasmodium falciparum phenylalanine tRNA synthetase provides opportunity for antimalarial drug development. Structure, 2022, 30, 962-972.e3.	1.6	4
7	Synthesis of skeletally diverse β-lactam haptens for the <i>in vitro</i> diagnosis of IgE-mediated drug allergy. Chemical Communications, 2022, 58, 5964-5967.	2.2	2
8	Stereochemical diversity as a source of discovery in chemical biology. Current Research in Chemical Biology, 2022, 2, 100028.	1.4	21
9	Crystal structures of the selenoprotein glutathione peroxidase 4 in its apo form and in complex with the covalently bound inhibitor ML162. Acta Crystallographica Section D: Structural Biology, 2021, 77, 237-248.	1.1	56
10	Targeted brachyury degradation disrupts a highly specific autoregulatory program controlling chordoma cell identity. Cell Reports Medicine, 2021, 2, 100188.	3.3	15
11	An expanded universe of cancer targets. Cell, 2021, 184, 1142-1155.	13.5	135
12	Cell-specific transcriptional control of mitochondrial metabolism by TIF1 $\hat{I}^3$ drives erythropoiesis. Science, 2021, 372, 716-721.	6.0	25
13	The Use of Informer Sets in Screening: Perspectives on an Efficient Strategy to Identify New Probes. SLAS Discovery, 2021, 26, 855-861.	1.4	8
14	Novel quaternary structures of the human prion protein globular domain. Biochimie, 2021, 191, 118-125.	1.3	4
15	The Rise of Molecular Glues. Cell, 2021, 184, 3-9.	13.5	252
16	Structural basis of malaria parasite phenylalanine tRNA-synthetase inhibition by bicyclic azetidines. Nature Communications, 2021, 12, 343.	5.8	19
17	Computational repurposing of therapeutic small molecules from cancer to pulmonary hypertension. Science Advances, 2021, 7, eabh 3794.	4.7	16
18	Recent achievements and current trajectories of diversity-oriented synthesis. Current Opinion in Chemical Biology, 2020, 56, 1-9.	2.8	67

#	Article	IF	CITATIONS
19	Characterization of the Prion Protein Binding Properties of Antisense Oligonucleotides. Biomolecules, 2020, 10, 1.	1.8	186
20	Bicyclic azetidines kill the diarrheal pathogen $<$ i>Cryptosporidium $<$ li>in mice by inhibiting parasite phenylalanyl-tRNA synthetase. Science Translational Medicine, 2020, 12, .	5.8	45
21	Prion protein lowering is a disease-modifying therapy across prion disease stages, strains and endpoints. Nucleic Acids Research, 2020, 48, 10615-10631.	6.5	69
22	An Activity-Guided Map of Electrophile-Cysteine Interactions in Primary Human T Cells. Cell, 2020, 182, 1009-1026.e29.	13.5	194
23	Phosphorylation-Inducing Chimeric Small Molecules. Journal of the American Chemical Society, 2020, 142, 14052-14057.	6.6	90
24	Multimodal small-molecule screening for human prion protein binders. Journal of Biological Chemistry, 2020, 295, 13516-13531.	1.6	14
25	Structure–activity relationships of GPX4 inhibitor warheads. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127538.	1.0	28
26	Plasticity of ether lipids promotes ferroptosis susceptibility and evasion. Nature, 2020, 585, 603-608.	13.7	420
27	Evaluating drug targets through human loss-of-function genetic variation. Nature, 2020, 581, 459-464.	13.7	115
28	Towards a treatment for genetic prion disease: trials and biomarkers. Lancet Neurology, The, 2020, 19, 361-368.	4.9	60
29	Unifying principles of bifunctional, proximity-inducing small molecules. Nature Chemical Biology, 2020, 16, 369-378.	3.9	124
30	Selective covalent targeting of GPX4 using masked nitrile-oxide electrophiles. Nature Chemical Biology, 2020, 16, 497-506.	3.9	229
31	Rhabdoid Tumors Are Sensitive to the Protein-Translation Inhibitor Homoharringtonine. Clinical Cancer Research, 2020, 26, 4995-5006.	3.2	14
32	Ligandâ€Enabled βâ€Methylene C(sp 3 )â^'H Arylation of Masked Aliphatic Alcohols. Angewandte Chemie, 2020, 132, 7857-7861.	1.6	14
33	Cytochrome P450 oxidoreductase contributes to phospholipid peroxidation in ferroptosis. Nature Chemical Biology, 2020, 16, 302-309.	3.9	396
34	Ligandâ€Enabled βâ€Methylene C(sp <sup>3</sup> )â^'H Arylation of Masked Aliphatic Alcohols. Angewandte Chemie - International Edition, 2020, 59, 7783-7787.	7.2	45
35	Water-Compatible Cycloadditions of Oligonucleotide-Conjugated Strained Allenes for DNA-Encoded Library Synthesis. Journal of the American Chemical Society, 2020, 142, 7776-7782.	6.6	58
36	Progress in Understanding Ferroptosis and Challenges in Its Targeting for Therapeutic Benefit. Cell Chemical Biology, 2020, 27, 463-471.	2.5	72

#	Article	IF	Citations
37	6-Phosphogluconate Dehydrogenase Links Cytosolic Carbohydrate Metabolism to Protein Secretion via Modulation of Glutathione Levels. Cell Chemical Biology, 2019, 26, 1306-1314.e5.	2.5	22
38	Optimization of PDE3A Modulators for SLFN12-Dependent Cancer Cell Killing. ACS Medicinal Chemistry Letters, 2019, 10, 1537-1542.	1.3	17
39	A Compendium of Genetic Modifiers of Mitochondrial Dysfunction Reveals Intra-organelle Buffering. Cell, 2019, 179, 1222-1238.e17.	13.5	109
40	Small-Molecule and CRISPR Screening Converge to Reveal Receptor Tyrosine Kinase Dependencies in Pediatric Rhabdoid Tumors. Cell Reports, 2019, 28, 2331-2344.e8.	2.9	24
41	Metabolomic adaptations and correlates of survival to immune checkpoint blockade. Nature Communications, 2019, 10, 4346.	5.8	139
42	Small-molecule targeting of brachyury transcription factor addiction in chordoma. Nature Medicine, 2019, 25, 292-300.	15.2	120
43	1980s Camelot. Journal of Antibiotics, 2019, 72, 323-323.	1.0	0
44	DNA Barcoding a Complete Matrix of Stereoisomeric Small Molecules. Journal of the American Chemical Society, 2019, 141, 10225-10235.	6.6	79
45	The landscape of cancer cell line metabolism. Nature Medicine, 2019, 25, 850-860.	15.2	350
46	Modular, stereocontrolled C $\langle \text{sub} \rangle \hat{1}^2 \langle \text{sub} \rangle \hat{a} \in \text{H/C} \langle \text{sub} \rangle \hat{1}_{\pm} \langle \text{sub} \rangle \hat{a} \in \text{C}$ activation of alkyl carboxylic acids. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 8721-8727.	3.3	39
47	A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis. Nature Communications, 2019, 10, 1617.	5.8	499
48	Prion protein quantification in human cerebrospinal fluid as a tool for prion disease drug development. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 7793-7798.	3.3	41
49	DNA-Compatible [3 + 2] Nitrone–Olefin Cycloaddition Suitable for DEL Syntheses. Organic Letters, 2019, 21, 1325-1330.	2.4	58
50	Domain-specific Quantification of Prion Protein in Cerebrospinal Fluid by Targeted Mass Spectrometry. Molecular and Cellular Proteomics, 2019, 18, 2388-2400.	2.5	22
51	Diacylfuroxans Are Masked Nitrile Oxides That Inhibit GPX4 Covalently. Journal of the American Chemical Society, 2019, 141, 20407-20415.	6.6	76
52	A Chemical Biology View of Bioactive Small Molecules and a Binderâ€Based Approach to Connect Biology to Precision Medicines. Israel Journal of Chemistry, 2019, 59, 52-59.	1.0	57
53	Antisense oligonucleotides extend survival of prion-infected mice. JCI Insight, 2019, 4, .	2.3	80
54	Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition. ELife, $2019, 8, .$	2.8	32

#	Article	lF	CITATIONS
55	Chemical probes and drug leads from advances in synthetic planning and methodology. Nature Reviews Drug Discovery, 2018, 17, 333-352.	21.5	182
56	RWEN: response-weighted elastic net for prediction of chemosensitivity of cancer cell lines. Bioinformatics, 2018, 34, 3332-3339.	1.8	21
57	Targeting Dependency on the GPX4 Lipid Peroxide Repair Pathway for Cancer Therapy. Biochemistry, 2018, 57, 2059-2060.	1.2	68
58	High Throughput Screen Identifies Interferon $\hat{I}^3$ -Dependent Inhibitors of <i>Toxoplasma gondii</i> Growth. ACS Infectious Diseases, 2018, 4, 1499-1507.	1.8	11
59	Synergistic Effects of Stereochemistry and Appendages on the Performance Diversity of a Collection of Synthetic Compounds. Journal of the American Chemical Society, 2018, 140, 11784-11790.	6.6	47
60	A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors. Nature Genetics, 2018, 50, 979-989.	9.4	168
61	Chemical Biology Towards Precision Medicine. Israel Journal of Chemistry, 2017, 57, 174-178.	1.0	0
62	Discovery of Antimalarial Azetidine-2-carbonitriles That Inhibit <i>P. falciparum</i> Dihydroorotate Dehydrogenase. ACS Medicinal Chemistry Letters, 2017, 8, 438-442.	1.3	49
63	A dataset of images and morphological profiles of 30 000 small-molecule treatments using the Cell Painting assay. GigaScience, 2017, 6, 1-5.	3.3	102
64	Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature, 2017, 551, 247-250.	13.7	1,043
65	Small-molecule inhibitors directly target CARD9 and mimic its protective variant in inflammatory bowel disease. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 11392-11397.	3.3	45
66	Synthesis of a Bicyclic Azetidine with In Vivo Antimalarial Activity Enabled by Stereospecific, Directed C(sp <sup>3</sup> )â€"H Arylation. Journal of the American Chemical Society, 2017, 139, 11300-11306.	6.6	104
67	Stereospecific Palladium-Catalyzed C–H Arylation of Pyroglutamic Acid Derivatives at the C3 Position Enabled by 8-Aminoquinoline as a Directing Group. Organic Letters, 2017, 19, 4424-4427.	2.4	38
68	Small-molecule studies identify CDK8 as a regulator of IL-10 in myeloid cells. Nature Chemical Biology, 2017, 13, 1102-1108.	3.9	46
69	A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles. Cell, 2017, 171, 1437-1452.e17.	13.5	2,281
70	Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature, 2017, 547, 453-457.	13.7	1,194
71	A small-molecule allosteric inhibitor of Mycobacterium tuberculosis tryptophan synthase. Nature Chemical Biology, 2017, 13, 943-950.	3.9	100
72	DIFFERENTIAL PATHWAY DEPENDENCY DISCOVERY ASSOCIATED WITH DRUG RESPONSE ACROSS CANCER CELL LINES. , 2017, 22, 497-508.		7

#	Article	IF	Citations
73	CTD2 Dashboard: a searchable web interface to connect validated results from the Cancer Target Discovery and Development Network. Database: the Journal of Biological Databases and Curation, 2017, 2017, .	1.4	23
74	Structural Insight into Allosteric Inhibition of Mycobacterium tuberculosis Tryptophan Synthase. FASEB Journal, 2017, 31, 765.12.	0.2	1
75	Real-Time Biological Annotation of Synthetic Compounds. Journal of the American Chemical Society, 2016, 138, 8920-8927.	6.6	39
76	Integrated genetic and pharmacologic interrogation of rare cancers. Nature Communications, 2016, 7, 11987.	5.8	45
77	Divergent Synthesis and Real-Time Biological Annotation of Optically Active Tetrahydrocyclopenta[ <i>c</i> )pyranone Derivatives. Organic Letters, 2016, 18, 6280-6283.	2.4	10
78	Inhibition of Zinc-Dependent Histone Deacetylases with a Chemically Triggered Electrophile. ACS Chemical Biology, 2016, 11, 1844-1851.	1.6	21
79	DisCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with <i>In Silico</i> Analysis to Identify Novel Therapeutic Targets. Clinical Cancer Research, 2016, 22, 3903-3914.	3.2	54
80	Diversity-oriented synthesis yields novel multistage antimalarial inhibitors. Nature, 2016, 538, 344-349.	13.7	214
81	Development of ML390: A Human DHODH Inhibitor That Induces Differentiation in Acute Myeloid Leukemia. ACS Medicinal Chemistry Letters, 2016, 7, 1112-1117.	1.3	51
82	Discovery of 8-Membered Ring Sulfonamides as Inhibitors of Oncogenic Mutant Isocitrate Dehydrogenase 1. ACS Medicinal Chemistry Letters, 2016, 7, 944-949.	1.3	21
83	Efficient Routes to a Diverse Array of Amino Alcohol-Derived Chiral Fragments. ACS Combinatorial Science, 2016, 18, 569-574.	3.8	23
84	Inhibition of Dihydroorotate Dehydrogenase Overcomes Differentiation Blockade in Acute Myeloid Leukemia. Cell, 2016, 167, 171-186.e15.	13.5	353
85	A genetic basis for the variation in the vulnerability of cancer to DNA damage. Nature Communications, 2016, 7, 11428.	5.8	136
86	Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 13162-13167.	3.3	112
87	Development of Chemical Probes for Investigation of Salt-Inducible Kinase Function <i>in Vivo</i> ACS Chemical Biology, 2016, 11, 2105-2111.	1.6	57
88	Identification of cancer-cytotoxic modulators of PDE3A by predictive chemogenomics. Nature Chemical Biology, 2016, 12, 102-108.	3.9	72
89	Correlating chemical sensitivity and basal gene expression reveals mechanism of action. Nature Chemical Biology, 2016, 12, 109-116.	3.9	636
90	High-Throughput Luciferase-Based Assay for the Discovery of Therapeutics That Prevent Malaria. ACS Infectious Diseases, 2016, 2, 281-293.	1.8	84

#	Article	IF	Citations
91	The Power of Sophisticated Phenotypic Screening and Modern Mechanism-of-Action Methods. Cell Chemical Biology, 2016, 23, 3-9.	2.5	97
92	High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines. Nature Biotechnology, 2016, 34, 419-423.	9.4	245
93	High-Throughput Assay and Discovery of Small Molecules that Interrupt Malaria Transmission. Cell Host and Microbe, 2016, 19, 114-126.	5.1	140
94	Discovery of bisamide-heterocycles as inhibitors of scavenger receptor BI (SR-BI)-mediated lipid uptake. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 2594-2598.	1.0	9
95	Kinase-Independent Small-Molecule Inhibition of JAK-STAT Signaling. Journal of the American Chemical Society, 2015, 137, 7929-7934.	6.6	29
96	Diversity-Oriented Synthesis Probe TargetsPlasmodium falciparumCytochrome b Ubiquinone Reduction Site and Synergizes With Oxidation Site Inhibitors. Journal of Infectious Diseases, 2015, 211, 1097-1103.	1.9	29
97	Advancing Biological Understanding and Therapeutics Discovery with Small-Molecule Probes. Cell, 2015, 161, 1252-1265.	13.5	135
98	Indolinyl-Thiazole Based Inhibitors of Scavenger Receptor-BI (SR-BI)-Mediated Lipid Transport. ACS Medicinal Chemistry Letters, 2015, 6, 375-380.	1.3	11
99	Niche-Based Screening in Multiple Myeloma Identifies a Kinesin-5 Inhibitor with Improved Selectivity over Hematopoietic Progenitors. Cell Reports, 2015, 10, 755-770.	2.9	21
100	Synthesis of Oxazocenones via Gold(I)-Catalyzed 8- <i>Endo</i> -Dig Hydroalkoxylation of Alkynamides. Organic Letters, 2015, 17, 418-421.	2.4	33
101	Benzo-fused lactams from a diversity-oriented synthesis (DOS) library as inhibitors of scavenger receptor BI (SR-BI)-mediated lipid uptake. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 2100-2105.	1.0	16
102	Discovery of a Small-Molecule Probe for V-ATPase Function. Journal of the American Chemical Society, 2015, 137, 5563-5568.	6.6	36
103	Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset. Cancer Discovery, 2015, 5, 1210-1223.	7.7	575
104	Small-molecule enhancers of autophagy modulate cellular disease phenotypes suggested by human genetics. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E4281-7.	3.3	56
105	<i>KRAS</i> Genomic Status Predicts the Sensitivity of Ovarian Cancer Cells to Decitabine. Cancer Research, 2015, 75, 2897-2906.	0.4	37
106	Linking Tumor Mutations to Drug Responses via a Quantitative Chemical–Genetic Interaction Map. Cancer Discovery, 2015, 5, 154-167.	7.7	57
107	Chemical perturbation of an intrinsically disordered region of TFIID distinguishes two modes of transcription initiation. ELife, 2015, 4, .	2.8	35
108	Quantitative-Proteomic Comparison of Alpha and Beta Cells to Uncover Novel Targets for Lineage Reprogramming. PLoS ONE, 2014, 9, e95194.	1.1	27

#	Article	IF	Citations
109	Atg16L1 T300A variant decreases selective autophagy resulting in altered cytokine signaling and decreased antibacterial defense. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 7741-7746.	3.3	298
110	Small-molecule control of cytokine function: new opportunities for treating immune disorders. Current Opinion in Chemical Biology, 2014, 23, 23-30.	2.8	20
111	Automated Structure–Activity Relationship Mining: Connecting Chemical Structure to Biological Profiles. Journal of Biomolecular Screening, 2014, 19, 738-748.	2.6	19
112	Small-molecule screening identifies inhibition of salt-inducible kinases as a therapeutic strategy to enhance immunoregulatory functions of dendritic cells. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 12468-12473.	3.3	68
113	Regulation of Ferroptotic Cancer Cell Death by GPX4. Cell, 2014, 156, 317-331.	13.5	4,187
114	Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells. Science, 2014, 343, 301-305.	6.0	1,371
115	NAMPT Is the Cellular Target of STF-31-Like Small-Molecule Probes. ACS Chemical Biology, 2014, 9, 2247-2254.	1.6	60
116	Toward performance-diverse small-molecule libraries for cell-based phenotypic screening using multiplexed high-dimensional profiling. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 10911-10916.	3.3	191
117	Diversity-Oriented Synthesis-Facilitated Medicinal Chemistry: Toward the Development of Novel Antimalarial Agents. Journal of Medicinal Chemistry, 2014, 57, 8496-8502.	2.9	33
118	Diversity-Oriented Synthesis Yields a New Drug Lead for Treatment of Chagas Disease. ACS Medicinal Chemistry Letters, 2014, 5, 149-153.	1.3	35
119	Synthesis of piperlogs and analysis of their effects on cells. Tetrahedron, 2013, 69, 7559-7567.	1.0	23
120	An Interactive Resource to Identify Cancer Genetic and Lineage Dependencies Targeted by Small Molecules. Cell, 2013, 154, 1151-1161.	13.5	615
121	Niche-based screening identifies small-molecule inhibitors of leukemia stem cells. Nature Chemical Biology, 2013, 9, 840-848.	3.9	103
122	Discovery of Small-Molecule Enhancers of Reactive Oxygen Species That are Nontoxic or Cause Genotype-Selective Cell Death. ACS Chemical Biology, 2013, 8, 923-929.	1.6	57
123	Crebinostat: A novel cognitive enhancer that inhibits histone deacetylase activity and modulates chromatin-mediated neuroplasticity. Neuropharmacology, 2013, 64, 81-96.	2.0	87
124	A Small-Molecule Inducer of PDX1 Expression Identified by High-Throughput Screening. Chemistry and Biology, 2013, 20, 1513-1522.	6.2	34
125	Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer. Cancer Research, 2013, 73, 6289-6298.	0.4	108
126	Multiplex Cytological Profiling Assay to Measure Diverse Cellular States. PLoS ONE, 2013, 8, e80999.	1.1	224

#	Article	IF	Citations
127	Synthesis, cellular evaluation, and mechanism of action of piperlongumine analogs. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 15115-15120.	3.3	200
128	The NIH's role in accelerating translational sciences. Nature Biotechnology, 2012, 30, 16-19.	9.4	14
129	Macrocyclic Hedgehog Pathway Inhibitors: Optimization of Cellular Activity and Mode of Action Studies. ACS Medicinal Chemistry Letters, 2012, 3, 808-813.	1.3	39
130	Diversity-Oriented Synthesis Yields a Novel Lead for the Treatment of Malaria. ACS Medicinal Chemistry Letters, 2012, 3, 112-117.	1.3	52
131	Development of small-molecule probes that selectively kill cells induced to express mutant RAS. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 1822-1826.	1.0	157
132	Identification of a selective small molecule inhibitor of breast cancer stem cells. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 3571-3574.	1.0	28
133	Niche-Based Screening Identifies Novel Small Molecules That Overcome Stromal Effects in Multiple Myeloma. Blood, 2012, 120, 571-571.	0.6	1
134	Syntheses of α-Pyrones Using Gold-Catalyzed Coupling Reactions. Organic Letters, 2011, 13, 2834-2836.	2.4	89
135	Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature, 2011, 475, 231-234.	13.7	939
136	Catalytic Diastereoselective Petasis Reactions. Angewandte Chemie - International Edition, 2011, 50, 8172-8175.	7.2	66
137	Discovery of histone deacetylase 8 selective inhibitors. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 2601-2605.	1.0	82
138	The DNA damage mark pH2AX differentiates the cytotoxic effects of small molecule HDAC inhibitors in ovarian cancer cells. Cancer Biology and Therapy, 2011, 12, 484-493.	1.5	42
139	Disease allele-dependent small-molecule sensitivities in blood cells from monogenic diabetes.  Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 492-497.	3.3	16
140	Organic synthesis toward small-molecule probes and drugs. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 6699-6702.	3.3	133
141	Quantifying structure and performance diversity for sets of small molecules comprising small-molecule screening collections. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 6817-6822.	3.3	98
142	Towards patient-based cancer therapeutics. Nature Biotechnology, 2010, 28, 904-906.	9.4	65
143	Small molecules of different origins have distinct distributions of structural complexity that correlate with protein-binding profiles. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 18787-18792.	3.3	302
144	Distinct Biological Network Properties between the Targets of Natural Products and Disease Genes. Journal of the American Chemical Society, 2010, 132, 9259-9261.	6.6	79

#	Article	IF	Citations
145	Small-molecule inducers of insulin expression in pancreatic $\hat{l}_{\pm}$ -cells. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 15099-15104.	3.3	62
146	Expanding Stereochemical and Skeletal Diversity Using Petasis Reactions and 1,3-Dipolar Cycloadditions. Organic Letters, 2010, 12, 5230-5233.	2.4	28
147	Small-Molecule Suppressors of Cytokine-Induced Î <sup>2</sup> -Cell Apoptosis. ACS Chemical Biology, 2010, 5, 729-734.	1.6	38
148	Stereochemical and Skeletal Diversity Arising from Amino Propargylic Alcohols. Organic Letters, 2010, 12, 2822-2825.	2.4	50
149	Binding Affinity and Kinetic Analysis of Targeted Small Molecule-Modified Nanoparticles. Bioconjugate Chemistry, 2010, 21, 14-19.	1.8	179
150	Using Expression and Genotype to Predict Drug Response in Yeast. PLoS ONE, 2009, 4, e6907.	1.1	14
151	Molecular diversity by design. Nature, 2009, 457, 153-154.	13.7	273
152	A small molecule that binds Hedgehog and blocks its signaling in human cells. Nature Chemical Biology, 2009, 5, 154-156.	3.9	273
153	Aziridines as intermediates in diversity-oriented syntheses of alkaloids. Tetrahedron Letters, 2009, 50, 3230-3233.	0.7	34
154	Syntheses of aminoalcohol-derived macrocycles leading to a small-molecule binder to and inhibitor of Sonic Hedgehog. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 6319-6325.	1.0	71
155	Synthesis and Conformationâ^'Activity Relationships of the Peptide Isosteres of FK228 and Largazole. Journal of the American Chemical Society, 2009, 131, 2900-2905.	6.6	107
156	Gold(I)-Catalyzed Coupling Reactions for the Synthesis of Diverse Small Molecules Using the Build/Couple/Pair Strategy. Journal of the American Chemical Society, 2009, 131, 5667-5674.	6.6	91
157	SnapShot: Ca2+-Calcineurin-NFATSignaling. Cell, 2009, 138, 210-210.e1.	13.5	90
158	Identification and Characterization of Small Molecule Inhibitors of a Class I Histone Deacetylase from <i>Plasmodium falciparum</i> Journal of Medicinal Chemistry, 2009, 52, 2185-2187.	2.9	75
159	Skeletally Diverse Small Molecules Using a Build/Couple/Pair Strategy. Organic Letters, 2009, 11, 1559-1562.	2.4	49
160	Unbiased discovery of in vivo imaging probes through in vitro profiling of nanoparticle libraries. Integrative Biology (United Kingdom), 2009, 1, 311.	0.6	20
161	Towards the Optimal Screening Collection: A Synthesis Strategy. Angewandte Chemie - International Edition, 2008, 47, 48-56.	7.2	507
162	The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature, 2008, 452, 230-233.	13.7	2,423

#	Article	IF	CITATIONS
163	Diversity Synthesis of Complex Pyridines Yields a Probe of a Neurotrophic Signaling Pathway. Organic Letters, 2008, 10, 2621-2624.	2.4	46
164	Small-Molecule Reagents for Cellular Pull-Down Experiments. Bioconjugate Chemistry, 2008, 19, 585-587.	1.8	13
165	Identification of Novel Epoxide Inhibitors of Hepatitis C Virus Replication Using a High-Throughput Screen. Antimicrobial Agents and Chemotherapy, 2007, 51, 3756-3759.	1.4	19
166	Quantifying fitness distributions and phenotypic relationships in recombinant yeast populations. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 10553-10558.	3.3	9
167	Synthesis and Cellular Profiling of Diverse Organosilicon Small Molecules. Journal of the American Chemical Society, 2007, 129, 1020-1021.	6.6	185
168	Fluorousâ€Based Smallâ€Molecule Microarrays for the Discovery of Histone Deacetylase Inhibitors. Angewandte Chemie - International Edition, 2007, 46, 7960-7964.	7.2	84
169	Complex αâ€Pyrones Synthesized by a Goldâ€Catalyzed Coupling Reaction. Angewandte Chemie - International Edition, 2007, 46, 8250-8253.	7.2	126
170	Identification of a Small-Molecule Inhibitor of Class Ia PI3Ks with Cell-Based Screening. Chemistry and Biology, 2007, 14, 371-377.	6.2	37
171	Rethinking relationships between natural products. Nature Chemical Biology, 2007, 3, 352-352.	3.9	7
172	Small molecules enhance autophagy and reduce toxicity in Huntington's disease models. Nature Chemical Biology, 2007, 3, 331-338.	3.9	572
173	Genetic basis of individual differences in the response to small-molecule drugs in yeast. Nature Genetics, 2007, 39, 496-502.	9.4	107
174	Ring-Opening and Ring-Closing Reactions of a Shikimic Acid-Derived Substrate Leading to Diverse Small Molecules. ACS Combinatorial Science, 2007, 9, 245-253.	3.3	23
175	A Soft-Drug Histone Deacetylase Inhibitor for Cutaneous T-Cell Lymphoma Blood, 2007, 110, 800-800.	0.6	2
176	Autophagy as a Target Pathway in Multiple Myeloma: A Forward Chemical Genetic Approach Blood, 2007, 110, 2510-2510.	0.6	0
177	An Oligomer-Based Approach to Skeletal Diversity in Small-Molecule Synthesis. Journal of the American Chemical Society, 2006, 128, 14766-14767.	6.6	76
178	Macrocycloadditions Leading to Conformationally Restricted Small Molecules. Organic Letters, 2006, 8, 2063-2066.	2.4	42
179	Microarray-based method for monitoring yeast overexpression strains reveals small-molecule targets in TOR pathway. Nature Chemical Biology, 2006, 2, 103-109.	3.9	98
180	Revealing Complex Traits with Small Molecules and Naturally Recombinant Yeast Strains. Chemistry and Biology, 2006, 13, 319-327.	6.2	38

#	Article	IF	CITATIONS
181	A Robust Small-Molecule Microarray Platform for Screening Cell Lysates. Chemistry and Biology, 2006, 13, 493-504.	6.2	124
182	Short Synthesis of Skeletally and Stereochemically Diverse Small Molecules by Coupling Petasis Condensation Reactions to Cyclization Reactions. Angewandte Chemie - International Edition, 2006, 45, 3635-3638.	7.2	159
183	Small Molecules, Big Players: the National Cancer Institute's Initiative for Chemical Genetics. Cancer Research, 2006, 66, 8935-8942.	0.4	69
184	Histone Deacetylase-6 (HDAC6) Modulates Akt and STAT3 Activity Via Heat Shock Protein (Hsp) 90 in Human Multiple Myeloma (MM) Cells Blood, 2006, 108, 3426-3426.	0.6	0
185	Design and Characterization of a Novel, Reverse Prodrug Histone Deacetylase Inhibitor for Cutaneous T-Cell Lymphoma Blood, 2006, 108, 4759-4759.	0.6	0
186	Discovery and Characterization of Small Molecule Inhibitors of Autophagy for Cancer Therapy Blood, 2006, 108, 2606-2606.	0.6	0
187	Small molecules: the missing link in the central dogma. Nature Chemical Biology, 2005, 1, 64-66.	3.9	294
188	Convergent Diversity-Oriented Synthesis of Small-Molecule Hybrids. Angewandte Chemie - International Edition, 2005, 44, 2249-2252.	7.2	74
189	From Solution-Phase to Solid-Phase Enyne Metathesis: Crossover in the Relative Performance of Two Commonly Used Ruthenium Pre-Catalysts. Chemistry - A European Journal, 2005, 11, 5086-5093.	1.7	14
190	Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 8567-8572.	3.3	571
191	Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 5992-5997.	3.3	332
192	Skeletal Diversity via a Folding Pathway:  Synthesis of Indole Alkaloid-Like Skeletons. Organic Letters, 2005, 7, 47-50.	2.4	116
193	Small-Molecule Diversity Using a Skeletal Transformation Strategy. Organic Letters, 2005, 7, 2535-2538.	2.4	58
194	Targeting the Protein Degradation Pathway in Multiple Myeloma with Synergistic, Selective Small Molecules Blood, 2005, 106, 2471-2471.	0.6	0
195	Finding new components of the target of rapamycin (TOR) signaling network through chemical genetics and proteome chips. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 16594-16599.	3.3	225
196	A Planning Strategy for Diversity-Oriented Synthesis. Angewandte Chemie - International Edition, 2004, 43, 46-58.	7.2	1,370
197	Synthetic Strategy toward Skeletal Diversity via Solid-Supported, Otherwise Unstable Reactive Intermediates. Angewandte Chemie - International Edition, 2004, 43, 1681-1685.	7.2	75
198	Modular Synthesis and Preliminary Biological Evaluation of Stereochemically Diverse 1,3-Dioxanes. Chemistry and Biology, 2004, 11, 1279-1291.	6.2	32

#	Article	IF	Citations
199	Relationship of Stereochemical and Skeletal Diversity of Small Molecules to Cellular Measurement Space. Journal of the American Chemical Society, 2004, 126, 14740-14745.	6.6	129
200	A Synthesis Strategy Yielding Skeletally Diverse Small Molecules Combinatorially. Journal of the American Chemical Society, 2004, 126, 14095-14104.	6.6	178
201	A Library of Spirooxindoles Based on a Stereoselective Three-Component Coupling Reaction. Journal of the American Chemical Society, 2004, 126, 16077-16086.	6.6	258
202	Identification and Characterization of Novel Small-Molecule Inhibitors of the Replication Checkpoint Blood, 2004, 104, 763-763.	0.6	0
203	Chemical Genomic Profiling of Biological Networks Using Graph Theory and Combinations of Small Molecule Perturbations. Journal of the American Chemical Society, 2003, 125, 10543-10545.	6.6	57
204	Expanding the Functional Group Compatibility of Small-Molecule Microarrays: Discovery of Novel Calmodulin Ligands. Angewandte Chemie - International Edition, 2003, 42, 2376-2379.	7.2	98
205	Structural Biasing Elements for In-Cell Histone Deacetylase Paralog Selectivity. Journal of the American Chemical Society, 2003, 125, 5586-5587.	6.6	115
206	Generating Diverse Skeletons of Small Molecules Combinatorially. Science, 2003, 302, 613-618.	6.0	371
207	From Knowing to Controlling: A Path from Genomics to Drugs Using Small Molecule Probes. Science, 2003, 300, 294-295.	6.0	263
208	Integration of Growth Factor and Nutrient Signaling. Molecular Cell, 2003, 12, 271-280.	4.5	186
209	Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 4389-4394.	3.3	980
210	Discovery of an Inhibitor of a Transcription Factor Using Small Molecule Microarrays and Diversity-Oriented Synthesis. Journal of the American Chemical Society, 2003, 125, 8420-8421.	6.6	184
211	Skeletal Diversity via a Branched Pathway:Â Efficient Synthesis of 29Â400 Discrete, Polycyclic Compounds and Their Arraying into Stock Solutions. Journal of the American Chemical Society, 2002, 124, 13402-13404.	6.6	124
212	Signaling Network Model of Chromatin. Cell, 2002, 111, 771-778.	13.5	353
213	An Alkynylboronic Ester Annulation: Development of Synthetic Methods for Application to Diversity-Oriented Organic Synthesis. Angewandte Chemie, 2002, 114, 3406-3410.	1.6	16
214	A Boronic Ester Annulation Strategy for Diversity-Oriented Organic Synthesis. Angewandte Chemie - International Edition, 2002, 41, 152-154.	7.2	82
215	An Alkynylboronic Ester Annulation: Development of Synthetic Methods for Application to Diversity-Oriented Organic Synthesis. Angewandte Chemie - International Edition, 2002, 41, 3272-3276.	7.2	66
216	Dissecting glucose signalling with diversity-oriented synthesis and small-molecule microarrays. Nature, 2002, 416, 653-657.	13.7	383

#	Article	IF	Citations
217	Deacetylase Enzymes. Chemistry and Biology, 2002, 9, 3-16.	6.2	513
218	Exploiting Siteâ <sup>^</sup> Site Interactions on Solid Support to Generate Dimeric Molecules. Organic Letters, 2001, 3, 1185-1188.	2.4	46
219	An Alkylsilyl-Tethered, High-Capacity Solid Support Amenable to Diversity-Oriented Synthesis for One-Bead, One-Stock Solution Chemical Genetics. ACS Combinatorial Science, 2001, 3, 312-318.	3.3	110
220	A one-bead, one-stock solution approach to chemical genetics: part 1. Chemistry and Biology, 2001, 8, 1167-1182.	6.2	117
221	A one-bead, one-stock solution approach to chemical genetics: part 2. Chemistry and Biology, 2001, 8, 1183-1195.	6.2	101
222	Asymmetric Catalysis in Diversity-Oriented Organic Synthesis: Enantioselective Synthesis of 4320 Encoded and Spatially Segregated Dihydropyrancarboxamides. Angewandte Chemie - International Edition, 2001, 40, 3417-3421.	7.2	78
223	Synthesis of 7200 Small Molecules Based on a Substructural Analysis of the Histone Deacetylase Inhibitors Trichostatin and Trapoxin. Organic Letters, 2001, 3, 4239-4242.	2.4	140
224	Dissecting cellular processes using small molecules: identification of colchicine-like, taxol-like and other small molecules that perturb mitosis. Chemistry and Biology, 2000, 7, 275-286.	6.2	235
225	Small-Molecule Microarrays:Â Covalent Attachment and Screening of Alcohol-Containing Small Molecules on Glass Slides. Journal of the American Chemical Society, 2000, 122, 7849-7850.	6.6	205
226	Pairwise Use of Complexity-Generating Reactions in Diversity-Oriented Organic Synthesis. Organic Letters, 2000, 2, 709-712.	2.4	247
227	Printing Proteins as Microarrays for High-Throughput Function Determination. Science, 2000, 289, 1760-1763.	6.0	2,413
228	High-throughput screening of small molecules in miniaturized mammalian cell-based assays involving post-translational modifications. Chemistry and Biology, 1999, 6, 71-83.	6.2	191
229	The identification of myriocin-binding proteins. Chemistry and Biology, 1999, 6, 221-235.	6.2	88
230	Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements. Nature Structural Biology, 1999, 6, 953-960.	9.7	140
231	Small Molecule Inhibitor of Mitotic Spindle Bipolarity Identified in a Phenotype-Based Screen. Science, 1999, 286, 971-974.	6.0	1,638
232	Visualizing Functional Group Distribution in Solid-Support Beads by Using Optical Analysis. Chemistry - A European Journal, 1999, 5, 3528-3532.	1.7	40
233	Molecular Association between ATR and Two Components of the Nucleosome Remodeling and Deacetylating Complex, HDAC2 and CHD4. Biochemistry, 1999, 38, 14711-14717.	1.2	88
234	Printing Small Molecules as Microarrays and Detecting Proteinâ 'Ligand Interactions en Masse. Journal of the American Chemical Society, 1999, 121, 7967-7968.	6.6	445

#	Article	IF	Citations
235	Chromatin deacetylation by an ATP-dependent nucleosome remodelling complex. Nature, 1998, 395, 917-921.	13.7	620
236	Chemical genetics resulting from a passion for synthetic organic chemistry. Bioorganic and Medicinal Chemistry, 1998, 6, 1127-1152.	1.4	420
237	Exploring the Specificity Pockets of Two Homologous SH3 Domains Using Structure-Based, Split-Pool Synthesis and Affinity-Based Selection. Journal of the American Chemical Society, 1998, 120, 23-29.	6.6	42
238	DIMERIZATION AS A REGULATORY MECHANISM IN SIGNAL TRANSDUCTION. Annual Review of Immunology, 1998, 16, 569-592.	9.5	308
239	Cell-Specific Calcineurin Inhibition by a Modified Cyclosporin. Journal of the American Chemical Society, 1997, 119, 1805-1806.	6.6	37
240	Single-Step Synthesis of Cell-Permeable Protein Dimerizers That Activate Signal Transduction and Gene Expression. Journal of the American Chemical Society, 1997, 119, 5106-5109.	6.6	82
241	Regulatory intramolecular association in a tyrosine kinase of the Tec family. Nature, 1997, 385, 93-97.	13.7	261
242	Three-part inventions: intracellular signaling and induced proximity. Trends in Biochemical Sciences, 1996, 21, 418-422.	3.7	150
243	Dimeric ligands define a role for transcriptional activation domains in reinitiation. Nature, 1996, 382, 822-826.	13.7	264
244	Kombinatorische Synthese und mehrdimensionale NMRâ€Spektroskopie: ein Beitrag zum VerstÃndnis von Proteinâ€Ligandâ€Wechselwirkungen. Angewandte Chemie, 1995, 107, 1041-1058.	1.6	9
245	Rationales Design neuer Rezeptorâ€Ligandâ€Kombinationen. Angewandte Chemie, 1995, 107, 2313-2317.	1.6	6
246	Combinatorial Synthesis and Multidimensional NMR Spectroscopy: An Approach to Understanding Protein–Ligand Interactions. Angewandte Chemie International Edition in English, 1995, 34, 953-969.	4.4	42
247	Rational Design of Orthogonal Receptor–Ligand Combinations. Angewandte Chemie International Edition in English, 1995, 34, 2129-2132.	4.4	89
248	Structure of guanine-nucleotide-exchange factor human Mss4 and identification of its Rab-interacting surface. Nature, 1995, 376, 788-791.	13.7	60
249	Control of p70 S6 kinase by kinase activity of FRAP in vivo. Nature, 1995, 377, 441-446.	13.7	665
250	Proximity versus allostery: the role of regulated protein dimerization in biology. Chemistry and Biology, 1994, 1, 131-136.	6.2	80
251	Mechanistic studies of a signaling pathway activated by the organic dimerizer FK1012. Chemistry and Biology, 1994, 1, 163-172.	6.2	61
252	A mammalian protein targeted by G1-arresting rapamycin–receptor complex. Nature, 1994, 369, 756-758.	13.7	1,829

#	Article	IF	Citations
253	Signalling an interest. Nature Structural and Molecular Biology, 1994, 1, 417-420.	3.6	13
254	1 H and 15 N assignments and secondary structure of the Src SH3 domain. FEBS Letters, 1993, 324, 87-92.	1.3	49
255	1 H and 15 N assignments and secondary structure of the PI3K SH3 domain. FEBS Letters, 1993, 324, 93-98.	1.3	18
256	Immunophilin-sensitive protein phosphatase action in cell signaling pathways. Cell, 1992, 70, 365-368.	13.5	346
257	The mechanism of action of cyclosporin A and FK506. Trends in Immunology, 1992, 13, 136-142.	7.5	2,114
258	Natural Products as Probes of Cellular Function: Studies of Immunophilins. Angewandte Chemie International Edition in English, 1992, 31, 384-400.	4.4	149
259	Naturstoffe als Sonden zum Studium zellulÃrer Funktionen – Untersuchungen von Immunophilinen. Angewandte Chemie, 1992, 104, 413-430.	1.6	40
260	Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell, 1991, 66, 807-815.	13.5	3,938
261	The effect of the immunosuppressant FK-506 on alternate pathways of T cell activation. European Journal of Immunology, 1991, 21, 439-445.	1.6	80
262	Molecular cloning and overexpression of the human FK506-binding protein FKBP. Nature, 1990, 346, 671-674.	13.7	330
263	N-oxide promoted pauson-khand cyclizations at room temperature. Tetrahedron Letters, 1990, 31, 5289-5292.	0.7	327
264	On the Conformation and Structure of Organometal Complexes in the Solid State: Two Studies Relevant to Chemical Synthesis. Angewandte Chemie International Edition in English, 1990, 29, 256-272.	4.4	184
265	An Asymmetric Synthesis of (+)-Cryptone. Synthetic Communications, 1990, 20, 1159-1165.	1.1	10
266	A receptor for the immuno-suppressant FK506 is a cis–trans peptidyl-prolyl isomerase. Nature, 1989, 341, 758-760.	13.7	1,341
267	Fragmentation reactions of .alphaalkoxy hydroperoxides and application to the synthesis of the macrolide (.+)-recifeiolide. Journal of the American Chemical Society, 1980, 102, 6163-6165.	6.6	173
268	Chemical Strategies for Activity-based Proteomics. , 0, , 403-426.		1
269	Chemical Complementation: Bringing the Power of Genetics to Chemistry. , 0, , 199-226.		О
270	Diversity-oriented Synthesis., 0,, 483-518.		7

#	Article	IF	CITATIONS
271	Controlling Protein–Protein Interactions Using Chemical Inducers and Disrupters of Dimerization. , 0, , 227-249.		7
272	The Biarsenical-tetracysteine Protein Tag: Chemistry and Biological Applications. , 0, , 427-457.		1
273	Chemical Approaches to Exploit Fusion Proteins for Functional Studies. , 0, , 458-479.		1
274	Managerial Challenges in Implementing Chemical Biology Platforms. , 0, , 789-803.		1
275	Reverse Chemical Genetics– An Important Strategy for the Study of Protein Function in Chemical Biology and Drug Discovery. , 0, , 355-384.		1
276	Using Natural Products to Unravel Cell Biology. , 0, , 95-114.		3
277	Modular Synthesis of Cyclopropaneâ€Fused Nâ€Heterocycles Enabled by Underexplored Diazo Reagents. Angewandte Chemie, 0, , .	1.6	O
278	Chemical Biology of Kinases Studied by NMR Spectroscopy. , 0, , 852-890.		1
279	Drugs Targeting Protein–Protein Interactions. , 0, , 979-1002.		2
280	Chemical Biology– An Outlook. , 0, , 1143-1150.		0
281	Chemical Biology and Enzymology: Protein Phosphorylation as a Case Study. , 0, , 385-402.		O